{"organizations": [], "uuid": "27213c10b608c6617cd24385894e8dbfcb55e3a3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180117.html", "section_title": "Archive News &amp; Video for Wednesday, 17 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-approves-addition-of-overall-s/brief-fda-approves-addition-of-overall-survival-data-to-kyprolis-label-idUSASB0C1BF", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Approves Addition Of Overall Survival Data To Kyprolis Label", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.116, "site_type": "news", "published": "2018-01-18T05:43:00.000+02:00", "replies_count": 0, "uuid": "27213c10b608c6617cd24385894e8dbfcb55e3a3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-approves-addition-of-overall-s/brief-fda-approves-addition-of-overall-survival-data-to-kyprolis-label-idUSASB0C1BF", "ord_in_thread": 0, "title": "BRIEF-FDA Approves Addition Of Overall Survival Data To Kyprolis Label", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "amgen inc", "sentiment": "negative"}, {"name": "omib", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 17 (Reuters) - Amgen Inc:\n* FDA APPROVES ADDITION OF OVERALL SURVIVAL DATA TO KYPROLISÂ® (CARFILZOMIB) LABEL\n* AMGEN INC - U.S. FDA APPROVED SUPPLEMENTAL NEW DRUG APPLICATION TO ADD OVERALL SURVIVAL DATA FROM PHASE 3 TRIAL TO PRESCRIBING INFORMATION FOR KYPROLIS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-18T05:43:00.000+02:00", "crawled": "2018-01-18T16:26:21.005+02:00", "highlightTitle": ""}